Source: Seeking Alpha

XBiotech: XBiotech in antibody manufacturing deal with J&J unit Janssen

Read full article »
XBiotech's Competitors | XBiotech's News | XBiotech's Financials

March 20, 2023

GlobeNewswire

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which pe... See more »

March 18, 2023

GlobalNewswire

Press Release: Dupixent (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms o... See more »

March 20, 2023

GlobeNewswire

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which pe... See more »

March 18, 2023

GlobalNewswire

Press Release: Dupixent (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms o... See more »
Stay up-to-date with the latest news on XBiotech
Annual Revenue
$4M
Employees
100
John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating

80/100

Read more
Stay up-to-date with the latest news on XBiotech